MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Affimed N.V. (NASDAQ: AFMD)*
Organization & Developments: Affimed
Parents
Affimed N.V. (NASDAQ: AFMD)*
Children
2018: Affimed lands big, backloaded immunotherapy deal with Genentech, sending its stock into overdrive
2018: Affimed Therapeutics: Continued Upside Ahead_seekingalpha.com
2018: Affimed Therapeutics' Data Will Finally Trump Execution In 2018 - Affimed Therapeutics (NASDAQ:AFMD)
2018: Affimed tumbles as FDA puts brakes on T cell engager
2019: Affimed Lays Out Accelerated Pathway For AFM13 At R&D Day - Affimed Therapeutics (NASDAQ:AFMD)
2019: Affimed: Updates To Thesis, Meaningful Catalysts In 2020_seekingalpha.com
2019: Tug Of War In Focus: Affimed_seekingalpha.com
2020: Affimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-Oncology
2020: Affimed's Stockpile Of Partnerships Supports A Long-Term Investment
2021: Affimed: Preparing For A Bullish 2022
2022: Affimed N.V. is a clinical-stage immuno-oncology company set to be presenting data from its Phase 1/2 trial of AFM13 and NK cells to treat CD30-positive lymphomas.
2022: Affimed Redirects Focus to NK Combo in Rare Type of Lymphoma
2022: Affimed Stock: 3 Points For The Bulls_seekingalpha.com
2022: Affimed: Data Readout Of AFM13 This Quarter Could Push Company Forwardseekingalpha.com
Jumps
*Key People: Affimed
Finance & Acquisitions: Affimed